Studies have reported that and () polymorphisms may be associated with the risk to different cancers. However, the correlation between those variations and non-small-cell lung cancer (NSCLC) is still unclear. A total of 1,003 NSCLC patients and 901 noncancer controls were recruited in the study, to confirm the association of variations in gene with the risk of NSCLC. The SNPscan™ genotyping assay was used to obtain the genotypes of the four BTLA polymorphisms ( rs1982809 G>A, rs16859629 T>C, rs2171513 G>A, and rs3112270 A>G). It was found that rs1982809 polymorphism reduced the risk of NSCLC (GA vs. GG: adjusted odds ratio (OR) = 0.81, 95%confidence interval (CI) = 0.66-0.99, and = 0.043). However, the rs16859629, rs2171513, and rs3112270 polymorphisms showed no significant association between NSCLC patients and controls in overall comparison. In subgroup analyses, we found that rs1982809 polymorphism reduced the risk of NSCLC (nonsquamous cell carcinoma: GA vs. GG: adjusted OR = 0.79, 95%CI = 0.64-0.97, and = 0.026; AA/GA vs. GG: adjusted OR = 0.81, 95%CI = 0.66-0.99, and = 0.037; ≥59 years: GA vs. GG: = 0.036; never alcohol consumption: GA vs. GG: = 0.013; GA/AA vs. GG: = 0.016; body mass index (BMI) ≥ 24 kg/m: GA vs. GG: = 0.030; GA/AA vs. GG: = 0.041). The rs16859629 polymorphism increased the risk of the development of squamous cell carcinoma (CC vs. TT: adjusted OR = 9.85, 95%CI = 1.37-71.03, and = 0.023; CC vs. TT/TC: adjusted OR = 9.55, 95%CI = 1.32-68.66, and = 0.025). Taken together, the findings of the present suggest that rs1982809 and rs16859629 polymorphisms may influence the susceptibility to NSCLC in the Chinese population.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867466 | PMC |
http://dx.doi.org/10.1155/2021/9121824 | DOI Listing |
Radiat Oncol
January 2025
Department of Oncology, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing, 400010, China.
Background: Patients with non-small cell lung cancer (NSCLC) are prone to developing brain metastases (BMs), particularly those with epidermal growth factor receptor (EGFR) mutations. In clinical practice, treatment-naïve EGFR-mutant NSCLC patients with asymptomatic BMs tend to choose EGFR-tyrosine kinase inhibitors (TKIs) as first-line therapy and defer intracranial radiotherapy (RT). However, the effectiveness of upfront intracranial RT remains unclear.
View Article and Find Full Text PDFClin Cancer Res
December 2024
Baylor University Medical Center, Dallast, Texas, United States.
Purpose: Brentuximab vedotin (BV) is hypothesized to selectively deplete T regulatory cells (Tregs) that express CD30 and re-sensitize tumors to anti-(PD-1) therapy. This study evaluated responses to BV+pembrolizumab post PD-1 and explored corresponding biomarkers.
Methods: 55 patients with metastatic non-small cell lung cancer (NSCLC) and 58 with metastatic cutaneous melanoma received ≥1 dose of BV+pembrolizumab.
J Cancer
January 2025
Department of Respiratory and Critical Care Medicine, The Second People's Hospital of Jingdezhen, Jingdezhen, China.
The prevailing belief is that third-generation tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) (TGET) outperform first-generation EGFR-TKIs (FGET) in managing advanced-stage EGFR-mutated non-small cell lung cancer (NSCLC). However, this standpoint lacks substantiation in evidence-based medicine. Therefore, this meta-analysis was conducted to compare the efficacy and adverse effects (AEs) of these two categories.
View Article and Find Full Text PDFNagoya J Med Sci
November 2024
Department of Radiation Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Risk-adapted stereotactic body radiation therapy is preferred over conventional radiotherapy at the authors' institution based on the hypothesis that even with a lower than recommended dose, stereotactic body radiation therapy would yield better local control than conventional radiotherapy. This retrospective study was performed to verify the hypothesis. Data from 34 patients with non-small cell lung cancer, who underwent risk-adapted stereotactic body radiation therapy delivered in 4 fractions between 2012 and 2018, were analyzed.
View Article and Find Full Text PDFBMJ Open
January 2025
Clinical and Basic Research Team of TCM Prevention and Treatment of NSCLC, Department of Oncology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Chinese Medicine Guangdong Laboratory, Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, State Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Objectives: To conduct an umbrella review to extensively evaluate and summarise the evidence regarding the relationship between risk factors and the occurrence of brain metastasis in lung cancer.
Design: Umbrella review of systematic reviews and meta-analyses.
Data Sources: Four databases (PubMed, EMBASE, Web of Science and Cochrane Library) were searched from inception to 10 November 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!